Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Innovent Biologics (Suzhou) Co. Ltd. currently faces 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 6 distinct examiners, meaning each examiner is handling a single case. This broad distribution requires the company to manage multiple individual examiner relationships and prosecution styles simultaneously.
The portfolio spans 5 distinct art units, which is slightly fewer than the count of examiners involved. CUNNINGCHEN, KATHLEEN MARY is identified as the busiest examiner, though she only holds 1 pending office action. This indicates that the workload is not concentrated in any single individual's hands, but rather spread across a wide array of USPTO personnel.
With this distribution across 5 distinct art units, the company must manage a broad range of examiner perspectives and potential art unit-specific hurdles. The presence of a pending action per examiner suggests a lack of examiner concentration, requiring individualized strategies for each filing. This level of diversity in the prosecution team can lead to varied outcomes and timelines for the pending office actions currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558655 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | REDDIG, PETER J | — |
| 18262937 | SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF | HAUK TEODORO, PRICILA NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681904 | ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18294212 | ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOF | LEE, YIE CHIA | — |
| 18573602 | USE OF MAZDUTIDE | D' AMBROSIO, THEA | — |
| 18566197 | BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND USE THEREOF | SZPERKA, MICHAEL EDWARD | — |
| 18558655 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1642 | 1 |
| 1654 | 1 |
| 1641 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681904 | ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112DP | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18294212 | ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOF | LEE, YIE CHIA | 1642 | §112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18573602 | USE OF MAZDUTIDE | D' AMBROSIO, THEA | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18566197 | BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND USE THEREOF | SZPERKA, MICHAEL EDWARD | 1641 | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18558655 | FC MUTANT WITH ALTERED BINDING TO FC RECEPTOR | REDDIG, PETER J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18262937 | SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF | HAUK TEODORO, PRICILA NMN | 1645 | §102§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovent Biologics (Suzhou) Co. Ltd. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Kathleen Mary Cunningchen has the most, with 1 of Innovent Biologics (Suzhou) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
